Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines that target the chromatin regulatory system to treat cancer. The company operates within the biotechnology and oncology drug development industries, with a scientific emphasis on genetically defined cancers driven by mutations in chromatin remodeling complexes. Its approach is based on proprietary insights into chromatin biology, aiming to address cancer dependencies that have historically been difficult to drug.
The company’s primary value drivers are its internally developed oncology pipeline and strategic research collaborations. Foghorn Therapeutics was founded in 2015 by leading academic scientists to translate fundamental discoveries in chromatin regulation into therapeutic candidates. It became a publicly traded company in 2020, using proceeds to advance multiple programs into clinical development and expand its targeted protein degradation and synthetic lethality platforms.
Business Operations
Foghorn Therapeutics conducts its operations as a single reporting segment focused on the discovery and development of oncology therapeutics. Its core programs include FHD-286, a selective SMARCA4/2 ATPase inhibitor being developed for cancers with SWI/SNF complex mutations, and FHD-609, a BRD9 degrader developed in collaboration with Eli Lilly and Company. Revenue to date has primarily been derived from collaboration and license agreements rather than product sales, as the company does not yet have an approved commercial product.
Operations are primarily based in the United States, with research and development activities centered in Cambridge, Massachusetts. The company controls proprietary drug discovery platforms related to chromatin biology, medicinal chemistry, and targeted protein degradation. It operates through wholly owned subsidiaries and relies on third-party manufacturers and clinical research organizations to support clinical trials and development activities.
Strategic Position & Investments
Strategically, Foghorn Therapeutics is focused on advancing a differentiated pipeline of chromatin-targeting therapies while selectively leveraging partnerships to share development risk and extend its technological reach. A key component of this strategy is its collaboration with Eli Lilly and Company, which includes multiple targets and provides upfront payments, research funding, and potential milestone and royalty revenue. This partnership validates Foghorn’s platform while allowing the company to retain significant rights to internally developed assets.
The company continues to invest in expanding its understanding of chromatin biology and applying emerging technologies such as targeted protein degradation and precision oncology biomarkers. Capital has been allocated primarily toward advancing clinical trials, expanding discovery capabilities, and maintaining optionality for future strategic collaborations or acquisitions. No major acquisitions have been publicly disclosed to date.
Geographic Footprint
Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, within the Greater Boston biotechnology hub. Its primary operations, including research, development, and corporate functions, are based in the United States. Clinical trials are conducted across multiple sites, including international locations, depending on study design and regulatory requirements.
While the company does not maintain large-scale commercial operations abroad, its strategic collaborations and clinical development activities give it a global footprint. Through partnerships and clinical trial networks, Foghorn maintains an operational and scientific presence that extends to Europe and other regions involved in multinational oncology studies.
Leadership & Governance
Foghorn Therapeutics was founded by prominent leaders in cancer biology and chemical biology, including Jay Bradner, M.D., Stuart Schreiber, Ph.D., and Matthew Meyerson, M.D., Ph.D. The company is led by an executive team with experience in oncology drug development, public company management, and translational research. Leadership emphasizes scientific rigor, precision medicine, and disciplined capital allocation to advance high-impact oncology programs.
Key members of the leadership team include:
- Adrian Gottschalk – Chief Executive Officer
- Sherri M. Carbone – Chief Financial Officer
- Tom Necela, Ph.D. – Chief Scientific Officer
- Mark A. Garland, M.D. – Chief Medical Officer
The board and management collectively guide the company’s long-term strategy, with a focus on advancing chromatin-targeted therapies from discovery through clinical proof of concept while maintaining strong governance and regulatory compliance.